Evidence map›Paper›PMID 33718034›Full record

ArticleTranslational lung cancer research2021

TIPE3 promotes non-small cell lung cancer progression via the protein kinase B/extracellular signal-regulated kinase 1/2-glycogen synthase kinase 3β-β-catenin/Snail axis.

Qiang Li, Dongmei Yu, Zhengyuan Yu, Qian Gao, Ruifang Chen, Lin Zhou, Rong Wang, Yan Li, Yulan Qian, Jun Zhao and 4 more

Open access · diamondAbstract read
In one paragraph

Article in Translational lung cancer research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 2 countries.

Qiang LiDepartment of Oncology, the First Affiliated Hospital of Soochow University, Suzhou, China.
Dongmei YuDepartment of Oncology, the First Affiliated Hospital of Soochow University, Suzhou, China.
Zhengyuan YuDepartment of Oncology, the First Affiliated Hospital of Soochow University, Suzhou, China.
Qian GaoDepartment of Oncology, the First Affiliated Hospital of Soochow University, Suzhou, China.
Ruifang ChenDepartment of Oncology, the First Affiliated Hospital of Soochow University, Suzhou, China.
Lin ZhouDepartment of Oncology, the First Affiliated Hospital of Soochow University, Suzhou, China.
Rong WangDepartment of Oncology, the First Affiliated Hospital of Soochow University, Suzhou, China.
Yan LiDepartment of Oncology, Suzhou Ninth People's Hospital, Suzhou, China.
Yulan QianDepartment of Oncology, the First Affiliated Hospital of Soochow University, Suzhou, China.
Jun ZhaoDepartment of Cardio-Thoracic Surgery, the First Affiliated Hospital of Soochow University, Suzhou, China.
Rafael RosellCatalan Institute of Oncology, Badalona, Spain.
Min TaoDepartment of Oncology, the First Affiliated Hospital of Soochow University, Suzhou, China.
Yufeng XieDepartment of Oncology, the First Affiliated Hospital of Soochow University, Suzhou, China.
Chun XuDepartment of Cardio-Thoracic Surgery, the First Affiliated Hospital of Soochow University, Suzhou, China.
Soochow University · CNFirst Affiliated Hospital of Soochow University · CNInstitut Català d'Oncologia · ESNanchang University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTumor necrosis factor-α-induced protein 8-like 3 (TNFAIP8L3, also called TIPE3) has been shown to activate PI3K-AKT and MEK-ERK pathways. However, the roles of TIPE3 in progression of lung cancer are largely unknown.

methodsImmunohistochemistry and western blotting were carried out to analyze the expression of TIPE3 in lung cancer clinical tissues and cells. TIPE3-overexpressing and knock-down NSCLC cell lines were established by transfer of TIPE3 coding sequence and shRNA, respectively.

resultsWe demonstrated that TIPE3 was elevated in lung cancer tissues and cells. The expression level of TIPE3 was positively correlated with malignant clinicopathological characteristics of lung cancer patients, such as tumor size, pathologic stage, and lymph node metastasis. Knockdown of TIPE3 suppressed the proliferation and growth of NSCLC cells as well as their migration and invasion ability, whereas TIPE3 overexpression facilitated these biological processes. Mechanistic data showed that TIPE3 promoted AKT and ERK1/2 signaling, inactivated GSK3β activity, and enhanced the expression and transcriptional activity of β-catenin, Snail1, and Slug in NSCLC cells. Kinase or proteasome inhibition and β-Trcp or STUB1 knockdown assays further revealed that TIPE3 upregulated β-catenin, Snail1, and Slug via the AKT/ERK1/2-GSK3β pathway, in an ubiquitin-proteasome-dependent manner. More importantly, clinical data demonstrated that the expression level of TIPE3 was positively associated with the activation of AKT/ERK1/2-GSK3β-β-catenin/Snail pathway in lung cancer.

conclusionsOur findings indicate that upregulation of TIPE3 promotes the progression of human NSCLC considerably by activating β-catenin, Snail1, and Slug transcriptional signaling via the AKT/ERK1/2-GSK3β axis. Therefore, TIPE3 may represent a potential therapeutic target for NSCLC.

Indexed as

metastasisNon-small cell lung cancer (NSCLC)proliferation and growthprotein kinase B (AKT)/extracellular signal-regulated kinase 1/2 (ERK1/2)-glycogen synthase kinase 3β (GSK3β)-β-catenin/Snail axistumor necrosis factor-α-induced protein 8-like 3 (TNFAIP8L3, also called TIPE3)

Identifiers

PMID33718034
PMCPMC7947417
OpenAlexW3135002489

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.